Last update 21 Nov 2024

Abrocitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ABRO
+ [5]
Target
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
GB (08 Sep 2021),
RegulationPromising Innovative Medicine (GB), Breakthrough Therapy (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC14H21N5O2S
InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N
CAS Registry1622902-68-4

External Link

KEGGWikiATCDrug Bank
D11400Abrocitinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis, Atopic
GB
08 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Moderate Atopic DermatitisPhase 3
AU
07 Dec 2017
Moderate Atopic DermatitisPhase 3
CZ
07 Dec 2017
Severe Atopic DermatitisPhase 3
PL
07 Dec 2017
Severe Atopic DermatitisPhase 3
DE
07 Dec 2017
Severe Atopic DermatitisPhase 3
CA
07 Dec 2017
Severe Atopic DermatitisPhase 3
CZ
07 Dec 2017
Severe Atopic DermatitisPhase 3
AU
07 Dec 2017
Severe Atopic DermatitisPhase 3
HU
07 Dec 2017
Severe Atopic DermatitisPhase 3
GB
07 Dec 2017
Severe Atopic DermatitisPhase 3
US
07 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
26
(Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
tvxzlnmyty(eputwanlrf) = tbgabigwfe rxqwmkmcbz (ncihkklmuu, eueakodeck - gbpafqhagm)
-
31 May 2024
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
tvxzlnmyty(eputwanlrf) = taxkyjrocp rxqwmkmcbz (ncihkklmuu, gszxbcbhea - tydzuybhha)
Phase 2/3
-
(xokktacoxk) = jyaorvzcwa xzeqznmnjx (xumiloshhq )
Positive
05 May 2024
(xokktacoxk) = tygcrqgvqi xzeqznmnjx (xumiloshhq )
Not Applicable
90
eggnycacuh(mnevobvnah) = 23 ( 0.85/patient year ( PY )) czghpbffem (ojstolivmf )
-
11 Oct 2023
Phase 3
727
yrvmjavkfy(nxygubjgjs) = zuykloqhkx xncmnhugsp (vlcarevbhf )
Positive
11 Oct 2023
Dupilumab 300 mg Q2W
yrvmjavkfy(nxygubjgjs) = zrlfgcnxvw xncmnhugsp (vlcarevbhf )
Not Applicable
-
(hxdpetqfei) = kmieajttdi ijfeygcfch (joatofqjks )
-
05 Jul 2023
(hxdpetqfei) = yobgyfnxwh ijfeygcfch (joatofqjks )
Phase 3
3,155
(rtrhlidwgd) = yjbtuqyxbb sjmxhluvwh (fimakpechm )
-
05 Jul 2023
(rtrhlidwgd) = nmqbfbkdsm sjmxhluvwh (fimakpechm )
Not Applicable
1,195
pascrdytpa(vrrexjunye) = dlsnrlmfey nnxxtodahy (ntimkyevpc )
-
03 Jul 2023
pascrdytpa(vrrexjunye) = jaxknnhnrn nnxxtodahy (ntimkyevpc )
Phase 2
20
(Prurigo Nodularis)
lxvqdsmnes(miguiusmxb) = iamidlcbwn imnuaddqnw (tazmfbdoaz, zqtcofuedv - gbkddmlwav)
-
03 Jul 2023
(Chronic Pruritus of Unknown Origin)
lxvqdsmnes(miguiusmxb) = kwdoabittg imnuaddqnw (tazmfbdoaz, ecxueekgbm - qwuaopafin)
Phase 3
1,235
khthkwzynl(xqjgsdixyz) = incidence was higher in adolescents kcrztzgflo (ijtskzxxqk )
Positive
10 Apr 2023
Phase 2
46
Placebo
ddgugnxxch(kdurnrbsvi) = zfqcfoibla tymytgxxhx (yegifygcwe, swzoygdgul - ajhvsyicwj)
-
08 Feb 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free